Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00249808
Status:
COMPLETED
Last Update Posted:
2018-03-20
First Post:
2005-11-04
Brief Title:
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed Have a Contraindication to or Are Intolerant of Other Systemic Therapies
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Psoriasis |
Keywords:
| Name | View |
|---|---|
| Candidates for systemic therapy for psoriasis | View |